Skip to main content

Patient Search

KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story

https://momentum.vicc.org/2022/04/cancer-gave-me-clarity/

If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story.

https://momentum.vicc.org/2022/04/brighter-outlook/
Displaying 1 - 10 of 23

Study explores new urinary tract infection treatment

Submitted by sobecksm on

Vanderbilt's Neil Osheroff, PhD, is part of an international research collaboration resulting in what is on track to be the first new antibiotic treatment for uncomplicated urinary tract infections in more than 20 years.

https://news.vumc.org/2023/02/02/study-explores-new-urinary-tract-infection-treatment/
VUMC News & Communications
Locked

Clamping Down the Metabolic Pipeline to B Cells

Submitted by robbikm2 on

New research shows the nutritive needs of B cells are more flexible than previously thought, which could enable researchers to steer antibody production in the lymph nodes and spleen to better combat autoimmunity. Patients with high-risk diseases of the immune system, particularly systemic lupus erythematosus, could stand to benefit from the research findings. The study led by Mark Boothby, MD, and published in the Journal of Immunology, provides details regarding how murine B cells use different sugars as they mature into antibody-producing cells

https://discoveries.vanderbilthealth.com/2024/02/clamping-down-the-metabolic-pipeline-to-b-cells/
Vanderbilt Health
Locked

Research Snapshot: DNA replication discovery opens pathways to understanding and treating cancer, aging and degenerative disease

Submitted by sobecksm on

An international collaboration led by biochemist David Cortez reached revelatory conclusions in exploration of how cells tolerate DNA damage and genome instability. Est. reading time: 2 mins.

https://news.vanderbilt.edu/2023/05/02/research-snapshot-dna-replication-discovery-opens-pathways-to-understanding-and-treating-cancer-aging-and-degenerative-disease/
Marissa Shapiro
Locked

Study of CHS-114 in Participants With Advanced Solid Tumors

Head/Neck

This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Head/Neck
I
Choe, Jennifer
NCT05635643
VICC-DTHAN23184P

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Head/Neck

A non-randomized two-cohort study of neoadjuvant Cemiplimab or neoadjuvant Cemiplimab plus Fianlimab (CF) in patients with basal cell carcinoma of the head and neck. Enrollment in the dual-therapy cohort will begin after completion of enrollment in the monotherapy cohort. Patients will undergo at least 2 and up to 6 infusions of immunotherapy prior to surgical resection. If patients have progression on neoadjuvant treatment, they may switch to standard of care surgical resection or hedgehog inhibitors prior to surgery. The primary endpoints are objective response rate and disease control rate. Safety and surgical benefit rate (de-escalation of surgery) with preservation of key anatomic structures are secondary endpoints. Correlative endpoints include analysis of pre and post treatment primary tumor and blood samples compared for histology, tumor genetics and immune cell composition.
Head/Neck
II
Topf, Michael
NCT05929664
VICC-ITHAN23127

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Head/Neck

This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
Head/Neck
II
Choe, Jennifer
NCT05904080
ALLHNA092105

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Head/Neck

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection.
Head/Neck
II/III
Topf, Michael
NCT04333537
NRGHN006

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Multiple Cancer Types

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Breast, Gastrointestinal, Gynecologic, Head/Neck, Lung, Melanoma, Neuro-Oncology, Sarcoma, Urologic
II
Choe, Jennifer
NCT05564377
VICC-NTMDT23238

SMP-3124LP in Adults With Advanced Solid Tumors

Multiple Cancer Types

An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Breast, Head/Neck, Lung, Non Small Cell, Ovarian, Phase I, Uterine
I/II
Eng, Cathy
NCT06526819
VICC-DTPHI23348

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

Multiple Cancer Types

This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.
Head/Neck, Phase I
I/II
Lockney, Natalie
NCT05156060
VICCHNP2173